IMMEDICA PHARMA AB
BiotechIMMEDICA PHARMA AB is a biotechnology company focused on Oncology. Key products include LOARGYS.
IMMEDICA PHARMA AB's Key Drugs
IMMEDICA PHARMA AB's core commercial portfolio centers on LOARGYS, spanning Oncology — its most strategically important drugs approved in the last 15 years.
IMMEDICA PHARMA AB's Recent FDA Approvals
IMMEDICA PHARMA AB secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
IMMEDICA PHARMA AB's Therapeutic Areas
IMMEDICA PHARMA AB's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IMMEDICA PHARMA AB's Top Competitors
IMMEDICA PHARMA AB's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IMMEDICA PHARMA AB Pipeline Snapshot
IMMEDICA PHARMA AB has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 3 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LOARGYS leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-02-23
- Latest
- 2026-02-23
- Applications
- 1